testosterone replacement therapy in prostate cancer survivors with hypogonadism
A study investigated whether the use of testosterone replacement therapy (TRT) was safe and efficacious in improving sexual and physical function in men with hypogonadism who have undergone radical prostatectomy for low-grade prostate cancer (1):
- randomized, placebo-controlled, double-blind phase 2 clinical trial of 136 men 40 years and older
- TRT for 12 weeks significantly improved sexual activity, sexual desire, physical function, and peak aerobic performance (VO2 peak) compared to placebo without biochemical recurrence during treatment or the 3-month follow-up
Study authors concluded:
- TRT for 12 weeks in men treated with radical prostatectomy for low-grade prostate cancer significantly improved sexual activity, sexual desire, well-being, body composition, physical function, and aerobic performance compared to placebo without biochemical recurrence
- findings do not apply to men with high-grade prostate cancer or those treated with androgen deprivation therapy or radiation therapy
Reference:
- Bhasin S, Burnett AL, Gagliano-Jucá T, et al. Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial. JAMA Intern Med. Published online May 11, 2026.
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.